Qin Q et al. and Quéro et al. have reported a complete and durable response in 3 and 4 HL patients respectively, treated with an association of palliative normofractioned RT and anti-PD-1 [43,44]. The gene discussed is PDCD1; the disease is Hodgkins lymphoma.